AWM
SLS icon

Aevitas Wealth Management’s SELLAS Life Sciences SLS Stock Holding History

Aevitas Wealth Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1
Closed – – 299
2019
Q1 		$0 Hold
1
– – ﹤0.01% 397
2018
Q4 		$0 Buy
+1
New +$77 ﹤0.01% 451
2018
Q2 		– Sell
-1
Closed – – 471
2018
Q1 		$0 Buy
+1
New +$285 ﹤0.01% 469

Other funds holding SLS

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aevitas Wealth Management's SLS Position: Q2 2019 in Review

Aevitas Wealth Management sold out of SELLAS Life Sciences (SLS) in Q2 2019, closing a stake of 1 share.

Aevitas Wealth Management first reported a position in SLS in Q1 2018 and held it in 3 quarters. The position peaked at $0 in Q1 2019. 17 funds tracked by Wall St. Rank hold SLS as of Q2 2019.

  • Aevitas Wealth Management reported no remaining SELLAS Life Sciences position as of Q2 2019 after selling out during the quarter.
  • Aevitas Wealth Management sold 1 SELLAS Life Sciences share in Q2 2019.
  • Aevitas Wealth Management first reported a position in SELLAS Life Sciences in Q1 2018 and held it in 3 quarters.
  • Aevitas Wealth Management's SELLAS Life Sciences position peaked at $0 in Q1 2019.
  • 17 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2019.

Based on Aevitas Wealth Management's 13F filing for Q2 2019, filed 26 Jul 2019.